Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1702||SWOG||A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1706||SWOG||A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0281||GOG||A Randomized Phase II/III Study To Assess The Efficacy of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer. NCT # NCT02101788||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GI002||NRG||A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-0617||RTOG||A Randomized Phase III Comparison of Standard-Dose (60 Gy) versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|EAF151||ECOG-ACRIN||Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1512||SWOG||A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5191||ECOG-ACRIN||A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0198||GOG||A Randomized Study of Tamoxifen Versus Thalidomide (NSC # 66847) in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer; Cancer of the Fallopian Tube; and Primary Peritoneal Carcinoma after First Line Chemotherapy||Adult CIRB - Late Phase Emphasis||Completed|
|A031701||Alliance||A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations||Adult CIRB - Late Phase Emphasis||Available to Open|